ClinicalTrials.gg
CompletedNCT01613248Updated Jan 8, 2019Results posted

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

A Phase 2 interventional study of MK-1602 and Placebo-matching MK-1602 in Migraine, sponsored by Allergan. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
834
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Enrollment
6th of 14
834 · median 507
Started
2012
with 1 other
Phase 2
2 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
6 of 14
Allergan

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 2 in phase 2, and was the 1st registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 1 year history of migraine with or without aura as defined by International Headache Society (IHS) criteria 1.1 and/or 1.2
  • Migraines typically last between 4 to 72 hours, if untreated
  • ≥ 2 and ≤ 8 moderate or severe migraine attacks per month in each of

the two months prior to screening

  • Male, female who is not of , or female of

reproductive potential with a screening serum β-human chorionic gonadotropin (β-hCG) level consistent with a not-pregnant state, and who agrees to use acceptable

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation
  • Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches
  • History of predominantly mild migraine attacks or migraines that usually

resolve spontaneously in less than two hours

  • More than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening
  • Basilar-type or hemiplegic migraine headache
  • > 50 years old at age of migraine onset
  • Taking migraine prophylactic medication where the prescribed daily dose

has changed during the 3 months prior to screening and will not be changed

during the study

  • Taking a proton pump inhibitor (PPI) or a histamine receptor 2 (H2) blocker on a daily or near daily basis (> 3 days per week)
  • Taking the following medications from 1 month prior to screening through study period: potent cytochrome P450 (CYP) 3A4 inhibitors (e.g., cyclosporine, itraconazole, ketoconazole, fluconazole, erythromycin, clarithromycin, nefazodone, telithromycin, cimetidine, quinine, diltiazem, verapamil, and [HIV] protease inhibitors), moderate or marked inducers (e.g., rifampicin, rifabutin, barbiturates [e.g., phenobarbital and primidone], systemic , nevirapine, efavirenz, pioglitazone, carbamazepine, phenytoin, and St. Johns wort), or drugs with narrow therapeutic margins and potential for drug interactions in the CYP2C family (e.g., warfarin)
  • Participant is unable to refrain from consumption of grapefruit or grapefruit juice during study
  • History of to, or has experienced a serious adverse event

in response to 3 or more classes of drugs (prescription and over-the-counter)

  • Clinical or laboratory evidence of uncontrolled diabetes, human immunodeficiency virus (HIV) disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic disease
  • Other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, dementia or significant neurological disorders other than migraine. Patients who are currently being treated with non-prohibited medication for depression and symptoms are well controlled are eligible to participate
  • Participant is at imminent risk of self-harm
  • History of ≤ 5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • History of gastric or small intestinal surgery (including gastric bypass

surgery or banding), or presence of a disease that causes malabsorption

  • Participant has recent history (within the last year) of drug or alcohol abuse or dependence or is a user of recreational or illicit drugs
  • Participant is legally or mentally incapacitated
  • Donation of blood products or phlebotomy of > 300 ml within 8

weeks of study, or intent to donate blood products or receive

blood products within 30 days of screening and throughout study

  • Intent to donate eggs or sperm within the projected duration of the

study

  • Current participation in or participation within 30 days of screening

in a study with an compound or device

  • Previous exposure to MK-0974 and/or MK-3207
  • Use within the past 2 months of an opioid- or barbiturate-containing

analgesic for migraine relief

  • Inpatient or emergency department treatment of an acute migraine

attack within the past 2 months

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
834 participants (actual)

Study arms

  • Experimental
    MK-1602 1 mg

    MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.

    Drug: MK-1602 · Drug: Rescue medication

  • Experimental
    MK-1602 10 mg

    MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.

    Drug: MK-1602 · Drug: Rescue medication

  • Experimental
    MK-1602 25 mg

    MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.

    Drug: MK-1602 · Drug: Rescue medication

  • Experimental
    MK-1602 50 mg

    MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.

    Drug: MK-1602 · Drug: Rescue medication

  • Experimental
    MK-1602 100 mg

    MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.

    Drug: MK-1602 · Drug: Rescue medication

  • Placebo comparator
    Placebo

    Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.

    Drug: Placebo-matching MK-1602 · Drug: Rescue medication

Interventions

  • Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.

  • DrugPlacebo-matching MK-1602

    Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.

  • DrugRescue medication

    If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours, Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose

    PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.

    Time frame: 2 hours post-dose

  2. Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose

    PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.

    Time frame: 2 hours post-dose

  3. Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose

    An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.

    Time frame: Up to 48 hours post-dose

  4. Number of Participants With One or More Adverse Events Within 14 Days Post-Dose

    An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.

    Time frame: Up to 14 days post-dose

  5. Number of Participants Who Discontinued From Study Due to Adverse Events

    Time frame: Up to 5 weeks post-dose

Secondary outcomes

  1. Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose

    Phonophobia is sensitivity to loud sounds.

    Time frame: 2 hours post-dose

  2. Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose

    Photophobia is sensitivity to bright light.

    Time frame: 2 hours post-dose

  3. Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose

    Time frame: 2 hours post-dose

  4. Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose

    SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.

    Time frame: 2-24 hours post-dose

  5. Percentage of Participants Reporting SPF 2-48 Hours Post-Dose

    SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.

    Time frame: 2-48 hours post-dose

  6. Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose

    SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.

    Time frame: 2-24 hours post-dose

  7. Percentage of Participants Reporting SPR 2-48 Hours Post-Dose

    SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.

    Time frame: 2-48 hours post-dose

  8. Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose

    TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.

    Time frame: 2 hours post-dose

  9. Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose

    TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.

    Time frame: 2-24 hours post-dose

  10. Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose

    TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.

    Time frame: 2-48 hours post-dose

07

Results

Posted Sep 30, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Started139138139139139140
Completed110104106101104102
Not completed293433383538
Withdrew: Adverse event000100
Withdrew: Withdrawal by subject322501
Withdrew: Lost to follow-up574842
Withdrew: Study terminated by sponsor4688911
Withdrew: Physician decision889476
Withdrew: Lack of qualifying event91110111518
Withdrew: Pregnancy000100

Outcome measures

PrimaryPercentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose

PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose8.9 (4.4 to 15.8)5.6 (2.1 to 11.8)14.8 (8.7 to 22.9)21.4 (13.9 to 30.5)21.0 (13.6 to 30.0)25.5 (17.4 to 35.1)
PrimaryPercentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose

PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose44.6 (35.2 to 54.3)37.4 (28.2 to 47.3)52.8 (42.9 to 62.5)53.4 (43.3 to 63.3)57.1 (47.1 to 66.8)58.8 (48.6 to 68.5)
PrimaryNumber of Participants With One or More Adverse Events Within 48 Hours Post-Dose

An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.

Time frame:
Up to 48 hours post-dose
Reported as:
Number · participants
Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose
participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose283329212330
PrimaryNumber of Participants With One or More Adverse Events Within 14 Days Post-Dose

An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.

Time frame:
Up to 14 days post-dose
Reported as:
Number · participants
Number of Participants With One or More Adverse Events Within 14 Days Post-Dose
participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Number of Participants With One or More Adverse Events Within 14 Days Post-Dose333732243032
PrimaryNumber of Participants Who Discontinued From Study Due to Adverse Events
Time frame:
Up to 5 weeks post-dose
Reported as:
Number · participants
Number of Participants Who Discontinued From Study Due to Adverse Events
participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Number of Participants Who Discontinued From Study Due to Adverse Events000000
SecondaryPercentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose

Phonophobia is sensitivity to loud sounds.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose42.0 (32.7 to 51.7)45.8 (36.1 to 55.7)49.1 (39.3 to 58.9)55.3 (45.2 to 65.1)56.2 (46.2 to 65.9)60.8 (50.6 to 70.3)
SecondaryPercentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose

Photophobia is sensitivity to bright light.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose30.4 (22.0 to 39.8)37.4 (28.2 to 47.3)43.5 (34.0 to 53.4)39.8 (30.3 to 49.9)47.6 (37.8 to 57.6)54.9 (44.7 to 64.8)
SecondaryPercentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose
Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose62.5 (52.9 to 71.5)59.8 (49.9 to 69.2)67.6 (57.9 to 76.3)73.8 (64.2 to 82.0)68.6 (58.8 to 77.3)70.6 (60.7 to 79.2)
SecondaryPercentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose

SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.

Time frame:
2-24 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose6.2 (2.5 to 12.3)4.7 (1.5 to 10.6)9.3 (4.5 to 16.4)14.6 (8.4 to 22.9)15.1 (8.9 to 23.4)21.6 (14.0 to 30.8)
SecondaryPercentage of Participants Reporting SPF 2-48 Hours Post-Dose

SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.

Time frame:
2-48 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting SPF 2-48 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting SPF 2-48 Hours Post-Dose6.2 (2.5 to 12.3)4.7 (1.5 to 10.6)9.3 (4.5 to 16.4)14.6 (8.4 to 22.9)14.2 (8.1 to 22.3)20.6 (13.2 to 29.7)
SecondaryPercentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose

SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.

Time frame:
2-24 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose28.3 (20.2 to 37.6)17.8 (11.0 to 26.3)36.1 (27.1 to 45.9)39.8 (30.3 to 49.9)45.7 (36.0 to 55.7)46.1 (36.2 to 56.2)
SecondaryPercentage of Participants Reporting SPR 2-48 Hours Post-Dose

SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.

Time frame:
2-48 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting SPR 2-48 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting SPR 2-48 Hours Post-Dose25.0 (17.3 to 34.1)17.0 (10.4 to 25.5)32.4 (23.7 to 42.1)37.9 (28.5 to 48.0)42.9 (33.2 to 52.9)43.1 (33.4 to 53.3)
SecondaryPercentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose

TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.

Time frame:
2 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose8.0 (3.7 to 14.7)5.6 (2.1 to 11.8)13.9 (8.0 to 21.9)20.4 (13.1 to 29.5)20.0 (12.8 to 28.9)23.5 (15.7 to 33.0)
SecondaryPercentage of Participants Reporting TMF at 2-24 Hours Post-Dose

TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.

Time frame:
2-24 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose5.3 (2.0 to 11.2)4.7 (1.5 to 10.6)9.3 (4.5 to 16.4)12.6 (6.9 to 20.6)14.2 (8.1 to 22.3)20.6 (13.2 to 29.7)
SecondaryPercentage of Participants Reporting TMF at 2-48 Hours Post-Dose

TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.

Time frame:
2-48 hours post-dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose
percentage of participantsPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose5.3 (2.0 to 11.2)4.7 (1.5 to 10.6)9.3 (4.5 to 16.4)12.6 (6.9 to 20.6)13.2 (7.4 to 21.2)19.6 (12.4 to 28.6)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/113 (0%)15/113 (13.3%)
MK-1602 1 mg—0/107 (0%)22/107 (20.6%)
MK-1602 10 mg—0/108 (0%)13/108 (12%)
MK-1602 25 mg—0/104 (0%)15/104 (14.4%)
MK-1602 50 mg—1/106 (0.9%)14/106 (13.2%)
MK-1602 100 mg—0/102 (0%)17/102 (16.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
MyoclonusNervous system disorders0/1130/1070/1080/1041/1060/102
Most frequent other events
Most frequent other events
EventPlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mg
NauseaGastrointestinal disorders4/1137/1074/1086/1048/1067/102
Dry mouthGastrointestinal disorders4/1138/1072/1083/1044/1065/102
DizzinessNervous system disorders1/1138/1075/1083/1042/1066/102
SomnolenceNervous system disorders6/1135/1074/1085/1043/1064/102

Baseline characteristics

All Subjects as Treated Population included all randomized participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)PlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mgTotal
Mean40.5 ± 11.739.6 ± 10.741.1 ± 10.941.4 ± 11.540.7 ± 12.341.9 ± 11.040.8 ± 11.4
Age, Customized
Age, Customized(participants)PlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mgTotal
< 20 years1102206
20 to 29 years182119131916106
30 to 39 years422928323226189
40 to 49 years223642332333189
50 to 59 years191714162123110
60 to 64 years102589337
>= 65 years1100013
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMK-1602 1 mgMK-1602 10 mgMK-1602 25 mgMK-1602 50 mgMK-1602 100 mgTotal
Female999592919290559
Male14121613141281
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016 Aug;36(9):887-98. doi: 10.1177/0333102416653233. Epub 2016 Jun 6. PubMed 27269043 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Dec 2012, 5 months.

Results were first posted in Sep 2016, 3 years 9 months after primary completion.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2012
First posted
Jun 7, 2012
StartActual
Jul 1, 2012
Primary completionActual
Dec 1, 2012
CompletionActual
Dec 1, 2012
Results first posted
Sep 30, 2016
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01613248
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
Jul 1, 2012
Primary completion
Dec 1, 2012
Completion
Dec 1, 2012
Results posted
Sep 30, 2016
Last update
Jan 8, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion